Teva faces fresh Copaxone kickbacks case from Medicare providers as it defends against DOJ claims

For years, Teva has been defending itself against allegations that it used illegal Medicare co-pay schemes to fuel sales of its multiple sclerosis drug Copaxone.

Now, two months after the company reportedly weighed a settlement with the U.S. government in an ongoing case, seven private Medicare coverage providers brought a new lawsuit in a Kansas court.